BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...

Related Keywords

California ,United States ,Jeffrey Cohen ,Paul Tyahla ,Eric Goldstein ,Ralph Kern ,Chaim Lebovits ,California Institute For Regenerative Medicine ,Brainstorm Cell Therapeutics Inc ,Lifesci Advisors ,Drug Administration ,Cleveland Clinic Mellen Center ,Free Communications ,Nasdaq ,Brainstorm Cell Therapeutics Ltd ,National Ms Society ,European Medicines Agency ,Research In Multiple Sclerosis ,European Committee For Treatment ,Brainstorm Cell Therapeutics ,Efficacy Study ,Progressive Multiple ,European Committee ,Multiple Sclerosis ,Experimental Therapeutics ,Chief Executive Officer ,Chief Medical Officer ,Storm Cell Therapeutics ,Orphan Drug ,California Institute ,Regenerative Medicine ,Harbor Statement ,Sci Advisors ,Cell Therapeutics ,